Who are Oral lumbrokinase DLBS1033's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natto extract (Nattokinase).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-lumbrokinase-dlbs1033.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral lumbrokinase DLBS1033 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral lumbrokinase DLBS1033 (Oral lumbrokinase DLBS1033) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic enzyme. Area: Cardiovascular.

marketed Fibrinolytic enzyme Fibrin; plasminogen activation pathway Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oral lumbrokinase DLBS1033 (Oral lumbrokinase DLBS1033) — Universitas Sebelas Maret. Lumbrokinase is a fibrinolytic enzyme derived from earthworm that breaks down fibrin clots and improves blood flow.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral lumbrokinase DLBS1033 TARGET	Oral lumbrokinase DLBS1033	Universitas Sebelas Maret	marketed	Fibrinolytic enzyme	Fibrin; plasminogen activation pathway
Natto extract (Nattokinase)	Natto extract (Nattokinase)	Changhua Christian Hospital	marketed	Fibrinolytic enzyme	Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic enzyme class)

Changhua Christian Hospital · 1 drug in this class
Universitas Sebelas Maret · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral lumbrokinase DLBS1033 — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-lumbrokinase-dlbs1033. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab